Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amanda Lawson

Nurse Practitioner Greensboro, NC Nurse Practitioner

NPI 1255954244 CMS profile 10837213

5921 W Friendly Ave Ste D, Greensboro, NC 27410

Open in the dashboard

General payments

$2,735

147 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Lawson of Greensboro, NC is reported in the CMS Open Payments database as having received $2,735 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $54 3
2024 General $506 27
2023 General $190 15
2022 General $731 39
2021 General $1,253 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Lawson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amanda Lawson were reported at $54. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amanda Lawson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,253 $135 $40–$426 $132
2022 $731 $152 $48–$470 $149
2023 $190 $166 $54–$529 $160
2024 $506 $173 $55–$556 $164
2025 $54 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $686 39 payments
  2. Novo Nordisk Inc $374 21 payments
  3. Forte Bio-Pharma LLC $337 1 payment
  4. Lilly USA, LLC $268 22 payments
  5. Abbott Laboratories $198 10 payments
  6. Biohaven Pharmaceuticals, Inc. $93 4 payments
  7. Collegium Pharmaceutical, Inc. $88 6 payments
  8. Amgen Inc. $82 6 payments
  9. Gilead Sciences, Inc. $76 4 payments
  10. AstraZeneca Pharmaceuticals LP $65 5 payments
  11. Other $468 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,735 147 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $458 23 payments
  2. NALOCET $337 1 payment
  3. PROLATE $337 1 payment
  4. RYBELSUS $278 14 payments
  5. FreeStyle Libre 3 $198 10 payments
  6. Ozempic $181 13 payments
  7. TRULICITY $166 15 payments
  8. VRAYLAR $139 10 payments
  9. NURTEC ODT $138 6 payments
  10. JARDIANCE $135 11 payments
  11. Other $1,234 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

851

Median for Nurse Practitioner: 389

Drug cost

$11,710

Median for Nurse Practitioner: $21,885

Branded share of claims

19%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Paxlovid Nirmatrelvir/Ritonavir Brand 13 $4,132
Boostrix Tdap Diphth,pertuss(Acell),tet Vac Brand 21 $1,469
Albuterol Sulfate Hfa Albuterol Sulfate Brand 45 $1,190
Rosuvastatin Calcium Generic 27 $437
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 31 $422
Omeprazole Generic 29 $381
Fluticasone Propionate Generic 20 $320
Losartan Potassium Generic 51 $295
Metoprolol Succinate Generic 21 $284
Prednisone Generic 77 $260

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$27,809

Of which drugs: $7,399

Medicare patients

155

Average age 75

Services billed

1,713

124 women, 31 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 41%
Osteoporosis 33%
Depression 24%
Ischemic heart disease 21%
Diabetes 19%
Chronic kidney disease 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 14 14 $4,034
Vaccine for influenza for injection into muscle 90662 Office 13 13 $1,044
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 880 $90

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $28
$28 — —
RYBELSUS
  • Novo Nordisk Inc $28
$28 — —
Ozempic
  • Novo Nordisk Inc $28
$28 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $27
$27 — —
JARDIANCE
  • Lilly USA, LLC $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record